What is Liraglutide?

The short answer

Liraglutide is a lab-made peptide that copies a hormone the gut makes after you eat. In the US, you need a prescription to get Liraglutide.

What it is
Copies the gut hormone GLP-1 and binds its receptor, with a lipid attached.
What people look into
Weight

4 sources
Status as of October 4, 2026
How we source
Ellum doesn't sell peptides.

By Ellum EditorialPublished October 6, 2026Updated October 12, 2026AI use

Get updates on Liraglutide

State

We'll store your email, your state, the page you're on and the peptides selected below (pre-selected from this page; untick any). Together these can reveal health interests. We use them only for what you tick below and to count sign-ups by state and peptide, without emails, to plan where the clinic opens and for reports that show only totals. Our hosting, database and email providers handle them for us. We pass them to a doctor or clinic only if you tick that box, and we don't sell them. Withdraw anytime with the unsubscribe link or at hello@ellumclinic.com. Consumer Health Data Privacy Policy

Ellum's sign-ups are for adults 18 and over.

Peptides: Liraglutide (1 selected) · edit

Peptides you're interested inLiraglutide

Add another molecule

What we may email you about

Notify me when an Ellum Clinic doctor can see me in my state

Send me updates on Liraglutide

More options (optional): research, doctor contact, paid offers

Contact me about taking part in research (optional)

Send my email, state and peptides to Ellum Clinic or a doctor licensed in my state, so they can contact me about care (optional)

Email me paid offers from clinics and health companies, picked for my peptides and state. Ellum sends them; the companies don't get my details (optional)

What it is

Type: GLP-1 receptor agonist (peptide)
Also known as: generic liraglutide, xultophy
How it works: Copies the gut hormone GLP-1 and binds its receptor, with a lipid attached.

Regulatory status

FDA-approved (Rx) How we label status

As of October 4, 2026, Liraglutide is an FDA-approved prescription drug for type 2 diabetes; chronic weight management.

See Liraglutide in the Index →

Federal (FDA): Approved Rx (Victoza NDA022341 2010; Saxenda NDA206321 2014; generic ANDA215503 2024)
503A compounding: Approved-drug component; liraglutide injection 'Currently in Shortage' on FDA DSP (checked 2026-10-04); no enforcement-discretion window found (as of October 4, 2026)

Timeline

Scroll sideways to see all columns.

Date	What happened	Source
May 1, 2026	FDA Federal Register notice proposes not to include liraglutide on the 503B bulks list for outsourcing facility compounding.	Federal Register, event of May 1, 2026, on federalregister.gov
June 26, 2026	FDA Federal Register notice extends the comment period on its proposal not to include liraglutide on the 503B bulks list.	Federal Register, event of June 26, 2026, on federalregister.gov

US enforcement actions

1 US enforcement action, in 2026.

Actions by US federal and state agencies whose documents name Liraglutide. Each row links to the government's own document.

Scroll sideways to see all columns.

Date	Agency	Action	Document
June 8, 2026	FDA	Warning letter	FDA document, warning letter, June 8, 2026, on fda.gov

Forms and brands

Scroll sideways to see all columns.

Name	Kind	Status	FDA status	As of
Saxenda	Brand	FDA-approved (Rx)	Approved Rx (NDA206321, 2014; weight management)	October 4, 2026
Victoza	Brand	FDA-approved (Rx)	Approved Rx (NDA022341, 2010; type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease)	October 12, 2026

References

Sources as of October 4, 2026